23andMe IPF Research Study

Completed

Conditions studied: Idiopathic Pulmonary Fibrosis

In brief

The long term goal of this study is to increase genetic understanding of IPF to enable the development of an effective drug for IPF that can improve the lives of those living with the condition.

Key facts

Study ID

NCT05028894

Run by

23andMe, Inc.

People needed

690

Starts

2020-06-05

Expected to finish

2023-05-05

Last updated by the study team

2024-12-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have been diagnosed with IPF or Hermansky-Pudlak syndrome (HPS)
• Are 18+ years old
• Live in the US

You may not qualify if…

• Have been diagnosed with sarcoidosis or hypersensitivity pneumonitis

Where it is running

• 23andMe — Sunnyvale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.